CRISPR Calls into Question Cancer Drug Target

The self-correcting nature of science has always seemed enigmatic to the uninitiated and armchair scientists. Yet, independent reproducibility is a hallmark of the proper scientific method and essential for validating appropriate therapeutic targets. Now, a team of scientists at Cold Spring Harbor Laboratory (CSHL) has published new evidence challenging previous research that the maternal embryonic leucine zipper kinase (MELK) gene is a good cancer drug target. Moreover, the researchers suggest